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Objectives. The purpose of this study was to examine the
possible role of nicotine in enhancing coagulation and to assess the
potential cardiovascular toxicity of transderiual nicotine therapy
for smoking cessation,
Background. Cigarette smoking Increases the risks of acute
coronary events. A likely contributing mechanism Is activation of
coagulation . The role of nicotine in enhancing coagulability has
not been resolved.
Methods . We cwmpured in a crossover study the effects of
cigarette smoking, transdermal nicotine and placebo transdermal
nicotine, each for S days, in 12 healthy smokers.
Resoles . Cigarette sniokhig increased the urinary excretion of
11-dehydro-thromboxane B
2
(reflecting thromboxane A2 genera-
tion) and increased plasma concentration of the platelet alpha-
granule constituents, platelet factor 4 and beta-thromboglobulin,
compared with placebo treatment, Indicating in vivo platelet
activation. Cigarette smoking was also associated with higher
levels of fibrinogen In plasma . Transdermal nicotine produced
plasma levels of nicotine In the same range as those during
smoking but had no effect on thromboxano A2 metabolite excre-
Cigarette smoking accelerates the development of athero-
sclerotic vascular disease and greatly increases the risk of
acute coronary events, particularly sudden death (1). A
likely mechanism that contributes to the effects of smoking
on the heart is activation of coagulation (2). The blood of
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Lion, platelet alpha-granule release or plasma fibrinogen, com-
pared with placebo. Excretion of 2,3-dinor-6-keto-PGF ta (reflect-
ing prostacyclin generation) was not significantly influenced by
any treatment. These results suggest that nicotine as such is not
responsible for the platelet activation or elrmtion of plasma
fibrinogen seen in smokers. However, we cannot exclude the
possibility that Intermittent bolus-like dosing of nicotine from
cigarettes could have different effects from those produced by
continually released transdermal nicotine . Other findings were
that cigarette smoking and transdermal nicotine treatment were
both associated with a higher white blood cell count compared
with the placebo patch condition, suggesting a direct effect of
nicotine to increase circulating white cells . Factor VII coagulant
activity (VII,,) was significantly lower during cigarette smoking,
than during either nicotine or placebo patch conditions.
Conclusions . Transdermal nicotine has less effect on platelet
activation and catecholamine release than does cigarette smoking,
and its use in smoking cessation treatment of patients with
coronary heart disease is likely to be safer than cigarette smoking .
(I Am Coll Cordial 1993;22:1159-6f)
smokers is known to coagulate more readily than the blood
of nonsmokers (3) . Smoking affects both platelet function
and coagulation factors. Effects on platelet aggregation have
been demonstrated by finding reduced platelet survival time
in smokers, increased circulating platelet aggregate :: with
release of platelet-specific proteins and splenic sequestration
of platelets after cigarette smoking (4,5) . Blef ding time is
shorter in smokers (6) . Increased sensitivity to platelets in
vitro to various aggre :,, ting chemicals has been reported in
some but not all studies (7,8) . It has been shown that
smokers generate more thromboxane A2, an eicosanoid
released by activated platelets, than do nonsmokers, sup-
porting the idea that smoking activates platelets (9-11) .
Smokers also have higher plasma levels of fibrinogen,
which is involved in the production of fibrin, is a cofactor for
platelet aggregation, increases blood viscosity and has been
found to be a risk factor for coronary heart disease (3,12,13) .
In addition, smokers have elevated red cell mass and ele-
vated white cell counts (3) .
Increased red cell mass, believed
to be a compensatory response to long-term carbon monox-
ide exposure, contributes to increased viscosity of the blood,
which is associated with a greater risk of coronary heart
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disease (13) . Increased white blood cell concentrations are
associated with an increased risk of ischemic heart disease,
although the causal nature and mechanism of this association
have not been determined .
The role of nicotine in enhancing coagulability has not
been resolved. Studies of the effects of nicotine on in vitro
platelet aggregation show that at high concentrations, nico-
tine inhibits aggregation responses to some stimuli while
enhancing responses to others (14) . No effects have been
seen at concentrations relevant to human smoking . Both
cigarette smoking and intravenous nicotine enhance cyclic
reduction in coronary artery blood flow in stenosed canine
coronary arteries (15). This phenomenon has been shown in
previous studies to be a consequence of platelet thrombi
formation. The eflbcts of nicotine in this system were
blocked by phentolamine, suggesting that catecholamines
mediate the nicotine response . A role for nicotine in causing
platelet aggregation in humans was suggested by a study (16)
showing a correlation between blood concentrations of nic .
otine and enhanced platelet aggregation responses to ciga-
rette smoking. It has likewise been reported (17) that circu-
lating platelet aggregates increased more in humans after
they smoked cigarettes containing tobacco than after they
smoked cigarettes that did not contain tobacco . However,
studies of people chewing nicotine chewing gum or consum-
ing smokeless tobacco (18, 19), both of which deliver nicotine
without combustion products, have reported no change in
platelet aggregation responses or excessive thromboxane A 2
generation. The latter studies suggest that nicotine does not
activate platelets. The conclusions of these studies must be
qualified, however, because nicotine chewing gum is not an
effective or consistent way of delivering nicotine, and be-
cause smokeless tobacco use may also be associated with
systemic absorption of other tobacco-derived chemicals that
could influence hemostatic function (20,21) .
Transdetmal nicotine has recently been developed as an
adjunct to smoking cessation therapy (22) . Transdermal
systems deliver nicotine over 24 h, resulting in fairly consis-
tent levels of nicotine, comparable to those seen in cigarette
smokers (23) . Understanding the effects of transdermal
nicer on hemostatis is important both in furthering our
understanding of the possible role of nicotine in smoking-
related cardiovascular events and in assessing the potential
safety of transdermal nicotine, particularly as it might be
used to aid smoking cessation in patients with coronary heart
disease.
Methods
Shldy ~, The subjects were 12 healthy men, aged
31 to 65 years (median 41 .5), who were regular cigarette
smokers. They smoked 20 to 40 cigaretteslday (median 30)
with Federal Trade Commission mean ± SD nicotine and tar
deliveries of 1 .2 ± 0.2 and 18.0 ± 3
.9 mg, respectively .
Subjects were highly dependent smokers as judged by a high
Fagerstrom scale score (24) (mean 9
.2, range 8 to 10,
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maximal score 11) and high baseline serum cotinine, the
major metabolite of nicotine (mean 355 ± 122, range 10 to
494). They had smoked for an average of 28 ± 10 years
(range 14 to 50) . Subjects were judged to be healthy on the
basis of physical examination, screening blood tests and
electrocardiography . They were instructed to abstain from
aspirin and other anti-inflammatory drugs for 2 weeks before
the study . Written informed consent was obtained from each
subject, and the study was approved by the University of
California, San Francisco Committee on Human Research .
Experimental protocol . Subjects were admitted to the
Clinical Study Center at San Francisco General Hospital for
16 days They were studied in three treatment blocks, each
of 5 days' duration. The treatments included cigarette smok-
ing, transdermal nicotine and placebo transdermal system .
The smoking and transdermal nicotine treatments always
occurred in the first two blocks, and the sequence was
balanced. The placebo transdermal system was always ad-
ministered last so as to avoid the possibility of nicotine
intoxication during the study . Nicotine intoxication might be
anticipated in subjects who had lost tolerance to the noxious
effects of nicotine during placebo treatment and then were
reexposed to nicotine in the subsequent treatment .
Each subject smoked 22 cigarettes of his own choice per
day, smoking at 40-min intervals beginning at 8 AM and
ending at 10 PM . The nicotine transdermal system (Nico-
derm, 21 mgfday) and placebos were supplied by Alza
Corporation and Marion Merrell Dow, Inc . Each transder-
mat nicotine system provides controlled delivery of nicotine
over 24 h, during which time 21 mg of nicotine is absorbed .
Patches were applied daily at 8 AM by the research staff .
During patch treatment periods, expired carbon monoxide
levels were mea . . -1 at random times during the day to
ensure that subjects were not surreptitiously smoking ciga-
rettes.
Urine was collected on days 3 and 4 of each treatment
block for measurement of concentrations of the thrombox-
ane A2 metabolite, l1-dehydro-thromboxane B 2 and the
prostacyclin metabolite 2,3-dinor-6-keto-PGF 1 ,. Urine was
collected on day 5 for measurement of catecholamines .
On day 4 of each block, blood samples (24 ml) were taken
at 8 AM (before smoking or the next patch was applied) and
then at 12 noon for platelet aggregation studies, concentra-
tions of platelet factor 4, beta thromboglobulin, Factor VII,
and fibrinogen and red and white blood cell and platelet
counts. Subjects were required to fast each morning until
after the second blood sample . On day 5 of each treatment
block, blood samples (5 ml each) were taken at 4-h intervals
from an indwelling venous catheter for measurement of
plasma concentrations of nicotine and blood carboxyhemo-
globin levels . In the smoking block, the time of blood
sampling was before smoking the next cigarette . On days
3 and 5. ambulatory blood pressure monitoring was also
performed . However, these data are the subject of another
report .
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Biochemical analyses. Urinary I1-dehydro-thromboxane
B, and 2.3-dinor-6-keto-PGF 1,, were analyzed at Vanderbilt
University by gas chromatography-chemical ionization mass
spectrometry, as described elsewhere (25,26) . Urine samples
had been collected with no preservatives anti stored frozen
in San Francisco until shipment to Nashvi'le in dry ice .
Urinary catecholamines were assayed by high performance
liquid chromatography using an electrochemical detector
(27,28). Plasma concentrations of nicotine and cotinine were
measured by gas chromatography using a nitrogen-selective
detector, as described by Jacob et al . (29), with modification
for use of a capillary column . Cabboxyhemoglobin was
measured using an IL-280 cooximeter . Exhaled carbon mon-
oxide was measured using an Ecolyzer . The platelet alpha-
granule proteins, platelet factor IV and beta-thromboglobu-
lin were measured by radioitnmunoassay . using commercial
kits. Plasma fibrinogen was measured using a fibrometer (30)
(BBL Fibrosystem model 7) . Factor VII coagulant activity
(Factor Vll e ) was measured by the Quick one-stage pro-
thrombin lime and Factor VII-dellcient plasma using a
fibrometer.
Platelet aggregation studies . Platelet aggregation was
studied in whole blood by both impedance aggregometry and
luminescence, the latter measuring adenosine triphosphate
release (31,32). Using whole blood avoids the need to
centrifuge and separate platelets, as is required when study-
ing platelet-rich plasma . Physical trauma to platelets may
result in some degree of activation . Whole-blood aggregom-
etry also allows aggregation to be studied in the presence of
leukocytes and erythrocytes, which may influence platelet
function in viva .
Blood was drawn by a separate venipuncture (without
using a tourniquet) into a syringe containing 1 :10 voi of 3 .870
sodium citrate. Platelet aggregation was performed in sili-
conized glass cuvettes, using a whole-blood aggregometer
(model 560, Chrono-Log Corporation) . as described else-
where (31) . Blood was diluted 1 :2 with isotonic saline
solution for whole-blood aggregation studies . Tests were
performed 30 to 60 min after blood sampling . The platelet
aggregation agonists that were tested included collagen
(0.5, 0.75 . I . 2 and 3 µg/ml), arachidonic acid (0 .25, 0
.5 and
1 .0 mmol/liter), adenosine diphosphate (15, 30 and 40 Amoll
5ter) and thrombin (I U/ml) .
Platelet responses that were measured included the max-
imal slope and amplitudes of the impedance response, as
well as maximal adenosine triphosphate release and the
adenosine triphosphate release ratio, defined as the ratio of
the maximal release of adenosine triphosphate by a particu-
lar agonist to the maximal release of adenosine triphosphate
in response to thrombin .
Statistical analysis . Treatmt.uts and, where appropriate .
sampling times (i .e ., 8 AM vs. 12 noon) were compared by
repeated measures analysis of variance . Post hoc compari-
sons were made using the Tukey test . Urinary cate-
cholamine excretion data were taken as the sum of 4-h
collections over 24 h and expressed per gram of creatinine to
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correct for occasional incomplete urine samples
. Circadian
plasma nicotine and carboxyhemoglobin concentration
data were expressed as area under the plasma or blood
concentration-time curve, estimated using the trapezoid
rule .
One subject, although claiming to smoke 30 cigarettes/
day before the study and actually burning 30 cigarettes/day
during the study, had a very low admission cotinine level and
low blood carboxyhemoglobin and plasma nicotine and
cotinine levels during the smoking phase of the study,
indicating that he was a noninhaler . The data were analyzed
with and without this subject's data . Exclusion of his data
had no effect in the outcome of the analyses, so his data were
included for the purposes of this report .
One subject appeared to have smoked a few cigarettes
surreptitiously on day 5 of his placebo treatment . Data were
analyzed with and without this subject deleted from analysis
of data derived from this day . This subject's nicotine and
carbon monoxide levels on day 4 of this same block were
consistent with nonsmoking, and, therefore, analysis of day
3 and 4 data include his data . Results of the analysis of the
day 5 data (i .e ., urinary catecholamine excretion) were
similar with or without this subject's data, so his data were
included in the final analysis .
Results
The total exposure to nicotine as estimated by the 24-h
area under the plasma concentration-time curve values
tended to be higher for cigarette smoking (451 ± 62 ng-h/ml
[mean ± SEMI) compared with the transdermal nicotine
system (357 ± 30 ng-h/ml) (Table 1) . The difference in area
under the curve values was not significant. However, be-
cause we were not able to sample peak concentrations, the
area under the curve values for cigarette smoking underes-
tintate the actual exposure to some extent . The temporal
pattern of plasma nicotine levels was different between the
two treatments, with higher daytime and evening levels
during cigarette smoking and higher overnight and early
morning levels with transdermal nicotine (Fig. I). Plasma
nicotine concentrations averaged 4 .4 ± 3.6 (mean ± SD) and
9.3 ± 3 .2 nglml at 8 AM and 28.4 ± 13
.8 and 15 .9 ± 12.3 ng/ml
at 8 PM during cigarette smoking and
transdermal nicotine
blocks, respectively . Carboxyhemoglobin
levels in the
smoking block averaged 2.2% and 6.6% at 8 AM and 8
PM,
respectively, with the expected circadian variation . Car-
boxyhemoglobin levels were <I% in the nonsmoking treat-
ment conditions .
Excretion of eicosanoid metabolites
and catecholamines.
Excretion of the thromboxane A 2
metabolite II-dehydro-
thromboxane B2 was similar on days 3 and 4
. The average
excretion of I l-dehydro-thromboxane B 2 was significantly
greater during cigarette smoking than with the transdermal
nicotine system or placebo patch (Table 1, Fig
. 2) . Excretion
of the prostacyclin metabolite 2 .3-dinor-6-keto-PGFI
0 was
greater on day 4 (the day of venipuncture for platelet studies)
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Table 1 . Plasma Nicotine Concentrations and Urinary Eicosanoid and Catecholamine Excretion
Values presented arc mean value t SE . 'Mean value, days 3 and 4
. tData based on day 5 excretion . *Overall analysis of variance ; treatment differences are
indicated based on posttests . AUC - area under the plasma concentration-time curve
; CS = cigarette smoking; PGI-M = 2.3-dinor4keto-PGF,,,; Plac =
placebo; TNS
-
transdannal nicotine system ; TX-M, 11 •dehydro-thromboxane 83 .
than on day 3 of each block . However, no significant
treatment effects were observed . Urinary excretion of epi-
nephrine and dopamine were significantly higher during
smoking than in other conditions, whereas the urinary nor-
epinephrine excretion rate tended to be higher (p < 0 .06)
during smoking (Fig. 3) .
Hemostatle biochemical studies . Concentrations of the
platelet alpha-granule constituents--platelet factor 4 and
beta thromboglobulin-were significantly higher during
smoking than with the other treatments (Table 2, Fig . 4) .
Figure 1. Average plasma nicotine and carboxyhemoglobin (COMB)
concentrations over 24 h, comparing cigarette smoking (22 ciga-
retteslday smoked at 40-min intervals from 8 AM to 10 PM) and
transdermal nicotine application (21 mg/day), day S of treatment
block. Data are expressed as mean value t SEM for 12 subjects .
M - midnight; N
a
noon .
CS > TNS CS > TNS CS > Plac
CS > Plac CS > Plac
TIME
Fibrinogen levels were higher, whereas Factor VII,, levels
were lower during smoking compared with the transdermal
nicotine and placebo treatments . The red blood cell count
was significantly lower in the placebo treatment compared
with other treatments. The white cell count was similar
during cigarette smoking and transdermal nicotine, whereas
it was significantly higher during cigarette smoking than with
placebo. Platelet counts were similar in all treatments.
Figure 2. Average urinary excretion of the thromboxane A x metab-
olite I 1-dehydro-thromboxane D3 (top) and the prostacyclin metab-
olite 2,3-dinor-6--keto-PGF,p (bottom) . comparing cigarette smoking,
transdermal nicotine and placebo treatments based on mean values
from 24-h urine collections on days 3 and 4 of the study . Data are
expressed as mean value ± SEM for 12 subjects . Overall analysis of
variance: p < 0.05 (top) and p = NS (bottom) .
CIGARETTE
SMOKING
TRANSDERMAL PLACEBO
NICOTINE PATCH
TRANSDERMAL
NICOTINE
PLACEBO
PATCH
Treatment
Plasma
Nicotine AUC
(nglml•h
)
Urinary TX-U -
(nglg creatinine)
Urinary PGI-M'
(nglg creatinine)
Urinary
Norepinephrinet
(µgig creatinine)
Urinary
Epinephrinet
(µgig creatinine)
Urinary
Dopaminet
(µ81g creatinine)
Cigarette smoking
451 : 62
611 t 47 176 t 11 176 t 23 28 ± 3 1,099 ± 86
Transdermall nicotine
356 ± 30
479 ± 34
159 ± 13 166 ® 25 21 ± 3 1,051 t 87
Placebo traasdermal system
-
496 = 33
160 t 13 172 t 20 22 ± 2 950 t 65
p value$
NS < 0 .05 NS < 0.06 < 0.05 < 0.05
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Figure 3. Average urinary excretion of norepinephrine,
epinephrine and dopamine comparing cigarette smoking
(solid bars), transdermal nicotine (open bars) and placebo
(hatched bars) based on 24-h urine collection on day 5
. Data
are expr::ssed as mean value ± SEM far 12 subjects
.
p values refer to overall analysis of variance.
Platelet aggregation . Platelet aggregation was examined
at several concentrations of aggregatory agents, as described
under Methods, but for simplicity, results are presented only
for representative concentrations at which all subjects had
complete data (Table 3). For adenosine diphosphate, there
was a significant time effect, with a lower slope of aggrega-
tion at 12 noon than at 8 AM. Treatment effects were seen
with the slope of adenosine diphosphate-induced aggrega-
tion, adenosine diphosphate-induced adenosine triphosphate
release and the adenosine triphosphate release ratio at
30 vmol/liter of adenosine diphosphate . Responses during
the placebo treatment were greater than those during smok-
ing or transdermal nicotine . Similar effects or trends were
seen at 15 and 40 µmol/liter of adenosine diphosphate as
well .
Arachidonic acid (0 .25 mmol/liter) produced a greater
rate (slope) of aggregation in the placebo period compared
with smoking or transdermal nicotine . This effect was seen
only at 0.25 mmol/liter, although the adenosine triphosphate
release ratio was significantly greater in the placebo period at
Table 2. Hemostatic Biochemical Studies*
W
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0.5 mmol/liter. Responses to collagen and thrombin were
similar in all treatments .
Discussion
Our crossover study unequivocally demonstrates that ciga-
rette smoking is associated with increased thromboxane A 2
generation and increased release of the platelet alpha-granule
constituents, platelet factor 4 and beta-thromboglobuln, indi-
cating in vivo platelet activation . In contrast, measurements
during transdermal nicotine treatment were similar to those
dutiug placebo patch treatment .
Methodologic issues. The study design has two method-
ologic issues that should be mentioned . First, each treatment
block is only 5 days. It is unknown how long the effects of
cigarette smoking on coagulation or on endothelial function
persist. Thus, we cannot say with certainty that our placebo
patch measurement values are representative of values of
long-term former smokers or nonsmokers . The relatively
brief duration of the treatment blocks would tend to bias the
*Average values day 4 of treatment block . tAnalysis for n =
11, in one subject, measurements were judged not to be accurate owing to difficulty in blood
drawing . #Overall analysis of variance ; treatment differences are indicated based on posttests
. Values presented are mean value ± SE . Abbreviations as in
Table 1 .
Treatment
Plasma
Nicotine
taglmi)
Platelet
Factor 4t
Mind)
Beta-
Thromboglobulint
(rwml)
Fibrinogen
(sngrdl)
Factor VII
(%)
kel Blood
Cells
(I0'ipq
White Blood
Cells
(10'tµ)
Platelets
(10'Ijd)
Cigarette sin' is
8AM 4.5± 1 .1 14.2±2.7 55±t 314 ± 13 90±6 4.9±0.1 7.0 ± 0.6 265 ± 20
12noon 25.8±5.2 11.3±2.5 49±5 312 ± 13 87 ± 5 5 .0 +_-0_1 6.6
± 0.3 262± 18
Transdermal nicotine
8AM 12.0 ± 2.0 12.2 ± 2 .0 52 ± 4 294±13 96±7
4.9±0.1 7.0*-0.6 260±21
12 noon 18.5 ± 1 .8 7.7 ± 0.7 42±3 299 ± 12
99 ± 7 5 .0 ± 0.1 6 .6 ± 0.4 256 ± 20
Placebo transdermal system
8AM 0.2±0.2 10.4±0.9 47±3 298 ± 14 103 ± 7
4.6±0.1 6.3 ± 0.5 266 ± 24
12 noon 0.5+0.3 7.9±0.9 42±3 299 ± 15 103 ± 7
4.7 ;•0.1 6.6±04 262 ± 21
p valuet < 0 .05 < 0 .05 < 0.05 <0.05
<0.05 <0.01 <0.05 NS
CS > TNS
at 8AM
CS > lilac
TNS > Plac
8 AM > 12 noon 8 AM > 12 noon CS > TNS TNS > CS
Plac > CS
CS > Pine
TNS > Plac
CS > Plac
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study to finding no differences between smoking and other
treatments . However, we found that several important in-
dexes of platelet activation did rapidly change (toward less
platelet activation) after 5 days of smoking cessation and that
these indexes are similar in people receiving transdermal
nicotine and placebo patch treatments . Second, the se-
quence of treatments was not fully balanced, with the
placebo patch treatment always occurring last . Although we
had a good medical reason for the sequence, it does poten-
Table 3. Platelet Aggregation Responses
00
s0
40
J
Figure 4. Plasma conccntra#ions of
platelet fac-
• tor 4, beta-thromboglobulin, Factor VIII and
fibrinogen comparing cigarette smoking (solid
bars), transdermal nicotine (open bars) and pla-
cebo (hatched bars). Averages of 8
AM and 12
noon measurements for each subject are shown
.
Data are expressed as mean value ± SEM for I I
subjects for platelet factor 4 and beta-thrombo-
globulin (one subject's data were lost because of
technical problems) and for 12 subjects for fibrin-
ogen and Factor VII . p values refer to overall
p
•
analysis of variance .
40
20
0
20
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tially confound the data analysis . For example, the lower red
blood cell count in the placebo condition almost certainty
reflects blood loss during the previous two study blocks . The
observed e ,j'tancement of aggregation responses to ade-
nosine diphosphatc and arachidonic acid during the placebo
patch condition may also reflect such blood loss, which can
be associated with release of younger, larger and more
reactive platelets (33) . In any case, the comparison between
cigarette smoking and transdermal nicotine treatments,
8 AM > 12 Play > CS Plac > CS Plac > TNS
0000
Plac > CS Ptac > TNS Plac > TNS CS > TNS
Plac > TNS
*Oreall analysis of variance ; treatment differences are indicated on the basis of posttests . Values presented are mean value ± SE. ADP = adenosine
dipbosphate; ATP = adanosine triphosphate; other abbreviations as in Table 1 .
Cigarette snaking
8 AM 7 .3 ± 1.7 0.5610.17 26.014 .8 16.81 3.9 0.80 ± 0.17 39.019.2 19 .2 1 1 .4 1 .36 ± 0.16 66.0 ± 5 .1 2.25 ± 0.20
12 noon 6.1±1.4 0.43±0.08 22.2±3 .6 16.1±2.7 0. 10.18 47.7±10 .1 17.2±1 .2 1.39±0.17 68.2±4 .8 2.35±0.17
7111KA i1111I
aicoliae
8 AM 6.611 .9 0.58±0.14 27.7±4 .8 I5.9±2.6 0.91±0.21 40.1±8.2 17.5±1 .2 1.43±0.25 66.4±5 .2 2.02±0.15
12 am 5.4±1 .1 0.50±0.00 24.6 ± 3 .9 10.2 ± 3.6 0.91±0.2644.9±13 .8 192±1 .2 1 .42 ± 0 .28 61.8±7 .1 2.15 ± 0.15
Placebo trancdermal
system
8 AM 9.8 ± 1 .6 0
.86 a 0,20
47,4
± 14.6 18 .9 ± 2 .2 1 .24 ± 0.25 48 .1 ± 7,5 16.7±1 .3 1 .41±0.16 65 .5 ± 5 .7 2.2l±0 .19
!2 Man 7 .1 ;1 .4 0.6910.13 33.3#5.6 15.0±2 .7 1 .19 ± 0.18 51 .9 ± 6 .0 17.4±1 .2 1.37±0.17 61 .3 ± 4.2 2.21 ± 0 .19
p+ ' < 0.05 < 0 .05 < 0.05 < 0.05 NS NS 4S NS NS NS
Arach(donic Acid Collagen
ADP(301unodliter) (0.25 mmolllter) (I )
Tbrombin
AT? AT? ATP ATP ATP ATP (1111161),
Release Release Release Release
Release Release ATP Release
Treatment Slope (amol) Ratio Slope (nmol) Ratio Slope (nmol) Ratio (nmol)
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which were administered in balanced sequence . i s sound and
makes the point that cigarette smoking and transdermal
nicotine have different effects on in vivo platelet activation .
Platelet activation and elcosanold excretion. Although not
a main part of our study, we observed that the slope of the
platelet aggregation response to adenosine diphosphate as
well as plasma levels of platelet factor 4 and beta-
thromboglobulin were higher at 8 AM than at 12 noon. The
risk of myocardial infarction, cerebral infarction and sudden
cardiac death is greatest in the early morning, and a morning
increase in in vitro platelet response to adenosine diphos-
phate, suggesting a role of platelet hyperaggregabiity fn the
morning, has been reported (34,35) . Our data on platelet
alpha-granule constituent concentrations provide support to
the idea that in vivo platelet activation is greater in the
morning as well .
Our findings of increased thromboxane A
2
metabolite but
unchanged prostacyclin metabolite excretion after smoking
are consistent with previous studies . Nowak et al . (9) and
Barrow et al . (11) showed that smokers excreted more
thromboxane metabolites as well as more prostacyclin me-
tabolites than did nonsmokers . Likewise, Lassila et al . (10)
found greater urinary excretion of both thromboxane and
prostacyclin metabolites in male identical twins who smoked
than in their nonsmoking twins . Wennmalm et al . (19) found
higher levels of thromboxane metabolite excretion in the
urine of smokers than in that of nonsmokers or snuff users
but found no difference in prostacyclin metabolite excretion
among the different groups . Because the subjects of
Wennmalm were younger than the subjects of Nowak or
Lassila, underlying smoking-related vascular disease . which
is more likely to be present in older smokers and which can
account for greater prostacyclin release, has been suggested
as a possible explanation for these findings. However, the
Barrow study (11), which also showed increased prostacy-
clin release, was also in young men .
The snuff users studied by Wennmalm et al . (19) had
exposures to nicotine similar to those of the cigarette smok-
ers, as estimated by urinary excretion of cotinine . Transder-
mal nicotine in our subjects likewise produced plasma levels
of nicotine in the same range as those observed during
cigarette smoking, although with a different temporal pat-
tern. Both of these studies suggest that the presence of
nicotine itself is not responsible for the platele, activation
seen in smokers. However, a role of nicotine caunot be fully
excluded because of pharmacodynamic considerations . Nic-
otine from cigarette smoke is absorbed rapidly into the
circulation and the brain, resulting in mental stimulation and
cardioacceleration, associated with catecholamine release
(36) . Nicotine delivered gradually produces much less stim-
ulation and less heart rate acceleration, owing both to
achieving lesser concentrations of nicotine in the blood and
the brain and to a greater time available for development of
tolerance (37) . Therefore, it is possible that the same dose of
nicotine administered by intermittent boluses, as by ciga-
rette smoking, might have a greater cardiovascular impact
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than that delivered continuously from a transdermal nicotine
delivery system .
Release of catecholamines is a mechanism by which nico-
tine could activate platelets. For example, the studies of Folts
and Bonebrake (15) showed that intravenous nicotine en-
hanced cyclic reduction in coronary artery blood flow in
stenosed canine ccronary arteries and that the effect was
blocked by phentolamine. This suggests that catecholamines
mediated the nicotine response . In people, intravenous infu-
sion of epinephrine increases plasma beta thromboglobulin
levels, indicating in vivo platelet activation (38). Our observa-
tion that urinary catecholamine excretion was higher with
cigarette smoking than with transdermal nicotine would be
consistent with the hypothesis that rapid delivery of nicotine
produces more catecholamine release and therefore more ac-
tivation of platelets .
Fibrinogen, white blood cell count and Factor VII . Fibrin-
ogen is an important component of the coagulation system .
It is involved in the production of fibrin, is a cofactor for
platelet aggregation and increases blood viscosity (12) . Fi-
brinogen levels are positively correlated with the risk of
coronary heart disease (13) . Cigarette smokers have higher
fibrinogen levels than those of nonsmokers (3), which is one
of the possible links between smoking and coronary heart
disease . Our study indicates that fibrinogen levels declined
significantly within 4 days of stopping smoking and that
fibrinogen levels are similar in nicotine and placebo patch
treatments .
White blood cell count is positively associated with the
risk of coronary heart disease (13,39) . White blood cell
counts on average are higher in smokers than in nonsmokers
(3,40) . It has been argued that the white blood cell count
predicts increased risk of coronary heart disease because it
reflects cigarette smoking (38), but other studies indicate an
association independent of smoking (13). Of considerable
interest in this regard is our finding that white cell count was
similar during smoking and transdermal nicotine but was
lower during the placebo patch period. This observation
suggests that nicotine itself may mediate leukocytosis . This
idea is supported by evidence that nicotine has chemotactic
effects on leukocytes (41) . If white cell count is an indepen-
dent risk for ischemir heart disease, exposure to nicotine
substitutes could contribute to that risk .
Factor VII plays a key role in the initiation of the
extrinsic coagulation system and contributes to the coagula-
bility of blood (12). High levels of Factor VII coagulant
activity (VII,) have been associated with an increased risk of
ischeinic heart disease (42). Of interest is that Factor VII
activity has been reported to increase in people who stop
smoking and decreases in nonsmokers who start or resume
smoking (43) . Our results confirm this observation
. We
found that smoking was associated with lower levels of
Factor VIII compared with transdermal nicotine or placebo
patch. The mechanism for this smoking effect on Factor VII
is unknown. It was speculated that changes in body mass
accompanying smoking accounted for the changes in Factor
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VII, (43), but in our 5-day study little change in body weight
occurred, whereas significant changes in Factor VII, activity
were observed .
In contrast to our findings with thromboxane A 2 metab-
olite excretion and platelet alpha-granule constituent con-
centrations, smoking did not increase platelet aggregation in
vitro. Published data on smoking and in vitro platelet aggre-
gation tests are conflicting, but most recent studies suggest
that smoking has either no effect or is associated with
reduced in vitro aggregation (7,8,44,45) . Presumably, this
reflects a situation in which platelets have been activated in
vivo, resulting in relative refractoriness to activation in
vitro, such as is believed to occur with exercise (8,46) .
Cilafeai Impikatiolla . Our data have clinical implications
with respect to the safety of transdermal nicotine . For all
measurements in which cigarette smoking was associated
with evidence of platelet activation and for increased plasma
fibrinogen compared with placebo, the transdermal nicotine
period resembled the placebo treatment period . Our findings
suggest that insofar as smoking contributes to acute coro-
nary events by enhancing platelet activation or increasing
fibrinogen, transdermal nicotine should not be associated
with such a risk . In ad4ition, cigarette smoking results in
exposure to carbon monoxide and numerous other toxic
combustion products that are likely also to contribute to
causation or aggravation of atherosclerotic vascular disease
(t). It should be noted that our patients were healthy .
Patients with coronary heart disease may have increased
platelet activation, higher fibrinogen levels and hyperlipid-
emia, all of which may influence clotting or fibrinolytic
mechanisms. The effects of nicotine on hemostatic unction
in such patients need to be examined . On the basis of
currently available data, our benefit-risk analysis concludes
that if transdermal nicotine systems can facilitate smoking
cessation in patients with coronary artery or peripheral
vascular disease, the benefit of such treatment appears to
substantially outweigh the risks of cigarette smoking or the
risks of transdermal nicotine as such .
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